---
title: "Lawrence M. Blatt Discloses Investment at Aligos Therapeutics with 5.6% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290738007.md"
description: "Lawrence M. Blatt, CEO and Chair of Aligos Therapeutics, disclosed a 5.6% stake in the company via a Schedule 13D filing on June 24, 2026. Blatt indicated potential plans to increase or decrease his holdings and signaled possible engagement in extraordinary corporate transactions, including mergers, take-private deals, or changes in board composition and management."
datetime: "2026-06-24T20:36:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290738007.md)
  - [en](https://longbridge.com/en/news/290738007.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290738007.md)
---

# Lawrence M. Blatt Discloses Investment at Aligos Therapeutics with 5.6% Stake

Lawrence M. Blatt, Ph.D., Chair, President and CEO of Aligos Therapeutics, disclosed a 5.6% stake in Aligos Therapeutics, Inc.'s common stock. He filed a Schedule 13D on Jun. 24, 2026, reflecting holdings measured as of Jun. 16, 2026. As the company's top executive, his stake could support moves ranging from deals to shifts in strategy.

**Investor Intent**

Blatt plans to keep reviewing his investment and could buy more shares, sell some, or use financial contracts to adjust his exposure. He also signaled that, as CEO and a director, he may push Aligos to consider major steps, including a merger, reorganization, or a take‑private deal.

He left the door open to governance and capital moves, noting he may encourage changes to the company’s stock buybacks or dividends and even leadership or board composition. In his words, he “may engage in discussions… to consider or explore extraordinary corporate transactions” and seek “changes… including changes in management or the composition of the Board.”

**Investor's Background**

Lawrence M. Blatt, Ph.D., is an American biotech executive and scientist who serves as Chair, President and CEO of Aligos Therapeutics. He focuses on building drug discovery companies in virology and liver disease with a hands‑on operating approach. Blatt previously co‑founded Alios BioPharma, which advanced antiviral programs and was acquired by Johnson & Johnson in 2014.

Original SEC Filing: Aligos Therapeutics, Inc. \[ ALGS \] - SCHEDULE 13D - Jun. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Aligos Q2 FY26 net loss narrows 91% to $1.5 million](https://longbridge.com/en/news/295103944.md)
- [Immune-focused biotech Attovia Therapeutics prices previously upsized IPO at $17, as expected](https://longbridge.com/en/news/294968074.md)
- [Palvella Therapeutics CEO joins Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/294958978.md)
- [Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday](https://longbridge.com/en/news/294710967.md)
- [Silexion Therapeutics director Amnon Peled resigns for personal reasons](https://longbridge.com/en/news/294550874.md)